HER2-Positive Breast Cancer | Clinical

Elderly Patients With HER2+ Advanced Breast Cancer Experience Poorer Outcomes, Increased Toxicity

December 09, 2020

Despite having similar disease characteristics and treatment patterns, elderly patients with HER2-positive advanced breast cancer aged ≥ 70 years experienced shorter chemotherapy durations than patients under the age of 70, as well as, poorer overall survival, and increased rates of adverse events in a real-world study.

Conference Preview: SABCS 2020

November 30, 2020

The most interesting developments and approvals in breast cancer treatment in the last year and expectations regarding data that will be presented on at the upcoming 2020 San Antonio Breast Cancer Symposium.

Strength of Anti-HER2 Therapy Combination Is Further Validated in Asian Population

November 14, 2020

Although the dual HER2 blockade combination is now considered a standard regimen for the treatment of patients with HER2-positive early-stage breast cancer, there are limited efficacy data regarding the use of the regimen in Asian populations.

HER2-Positive Breast Cancer Treatment Landscape Expands With Promise of New Therapies

November 02, 2020

In an interview with Targeted Oncology, William J. Gradishar, MD, discussed the current treatment options for patients with HER2-positive breast cancer, including the recently approved therapies from the FDA. He also shared his insights on treating patients with brain metastases, in particular.

Treatment Options for HER2+ Breast Cancer Open to Multiple Lines of Therapy and Subgroups

October 20, 2020

Until recently, few options existed for patients with HER2-positive breast cancer who progressed on earlier lines of therapy. Recent approvals of 3 drug combinations offer new tools that may prolong life and control brain metastases across lines of therapy.